Advanced Micro Devices is rapidly gaining share in the AI accelerator market, with 2024 data center revenue nearly doubling to $12.6B. The MI350 series, launching mid-2025 with 35x inference performance improvement and 288GB HBM3E memory, has secured deployment commitments from Microsoft, Meta, and OpenAI. Tier-one customer wins (Microsoft, Meta, OpenAI and Oracle) validate AMD's competitive positioning, while ROCm software progress narrows the ecosystem gap with Nvidia.

FE is ramping up grid modernization and regulated investments as AI-driven data centers continue to drive demand.

CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.

AEP's $72B capital plan and renewable buildout aim to lift efficiency and revenues, but reliance on a few REPs poses cash-flow risk.

Quantum Computing is betting on long-term scale, pouring capital into Fab 1 and future Fab 2 while accepting slower near-term sales from small, customized deployments.

Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.

ISRG's single-port platform posts 91% procedure growth, led by Korea, with U.S. momentum building as new tools and indications expand adoption.

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

CNBC's Kristina Partsinevelos reports on Nvidia as the semiconductor giant works to meet strong H200 demand from Chinese tech companies, according to Reuters.

Nebius is benefiting from the ongoing shortages in AI infrastructure capacity. The company plans to rapidly expand data center capacity.

In a year where the benchmark S&P 500 index managed to gain more than 17%, that flat performance could be alarming. Yet zooming out tells a more constructive story—Amazon is up more than 40% since April, has consistently beaten expectations each quarter, and continues to enjoy broad analyst support.

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4.

Total Voting Rights In conformity with the Disclosure Guidance and Transparency Rules, we hereby notify the market of the following: Shell plc's capital as at December 31, 2025, consists of 5,718,636,398 ordinary shares of €0.07 each. Shell plc holds no shares in Treasury.

QS and two auto giants, TM and TSLA, are ramping EV battery bets, from solid-state breakthroughs to new U.S. plants, as demand for longer-range EVs grows.

Stockholder approval enables closing of the Sonim asset sale in January 2026 NEXA to continue selling rugged phones and mobile hotspots under the Sonim brand Transaction allows Sonim to retire debt and provides working capital for new, independent business Public company to rebrand and focus exclusively on DNA X, a crypto trading platform San Diego, California--(Newsfile Corp. - December 31, 2025) - Sonim Technologies, Inc. (NASDAQ: SONM) today announced that its stockholders approved the previously announced Asset Purchase Agreement with NEXA® (formerly Social Mobile) at a special meeting held on December 30, 2025. The approval authorizes Sonim to complete the …

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CYPS317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of moderate to severe psoriasis. This IND filing represents a major advancement for FibroBiologics' chronic inflammatory disease pipeline and follows …

CLEVELAND, Dec. 31, 2025 /PRNewswire/ -- TransDigm Group Incorporated (NYSE: TDG) today announced it has entered into a definitive agreement to acquire Stellant Systems, Inc. ("Stellant" or "the Company"), a portfolio company of Arlington Capital Partners, for approximately $960 million in cash, including certain tax benefits. Stellant, headquartered in Torrance, California, is a leading global designer and manufacturer of high-power electronic components and subsystems serving the aerospace and defense end market.

Eightco holds over 10% of the current WLD supply in circulation Eightco's total holdings include 277,222,975 WLD, 11,068 ETH, and cash and stablecoins ofapprox. $69.2 million The company recently announced a share buyback program for up to $125 million Chairman Dan Ives and CEO Kevin O'Donnell to attend CES in Las Vegas to showcase Infinityby ORBS; invites everyone to connect and engage The Company is supported by a group of strategic and institutional investors including: Bitmine(BMNR), MOZAYYX, World Foundation, Wedbush, Coinfund, Discovery Capital Management,FalconX, Kraken, Pantera, GSR, Brevan Howard and more EASTON, Pa.

SAN CLEMENTE, Calif., Dec. 31, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 44th Annual J.P.

Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020 can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.